Observational studyPloS one2025
Analysing genome sequences and associated metadata during the COVID-19 pandemic in Iraq revealed points to be improved: An observational retrospective study.
Observational study in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic started in Wuhan China and rapidly transmitted worldwide, the illness is characterised by respiratory manifestations like coughing, breathing difficulties and pneumonia that could lead to death. Real-time whole genome sequencing of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) was adopted in many countries to track the infection dynamics and evolution of the virus. In parallel with the global efforts, genome sequencing trials were established in Iraq during the COVID-19 pandemic, however, this new approach has not been assessed yet. Therefore, for better readiness and improvement for future pandemics, here we obtained all genomes of SARS-CoV-2 virus from Iraq (182) that were deposited in National Center for Biotechnology Information (NCBI) during the period (2020-2023). Statistical analyses of sample size, distribution and other epidemiological parameters from associated metadata, as well as the quality of genome sequences were assessed. Our data analyses highlighted some drawbacks that could be improved, namely, that most genomic sequences (62%) were collected from only two cities, a low sample size was noticed and sequencing quality was inconsistent. There was a shortage and impairment of sequencing facilities especially those of the Ministry of Health. Consequently, genome sequencing should be achieved in centres that produce the best quality. The results revealed the importance of well-documented and high-quality sequences that represent many important cities in the country, which is crucial to draw a clear projection for health officials on infection dynamics and tracking viral evolution to help in taking successful steps towards infection control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.